semaglutide cardiovascular news today Semaglutide lowers cardiovascular events even without major weight loss, researchers report

GLP-1 receptor agonists such as semaglutide are changing the way type 2 diabetes and obesity are treated. But these drugs have also shown a surprising ability to improve cardiovascular health — and

22.78

★★★★☆4.8 (126)

Weight loss drug could reduce heart attack risk by 20%, study finds | Medical research

25.31

★★★★★4.9 (98)

FDA approves new Wegovy (semaglutide) indication to reduce cardiovascular death, heart attack, and stroke risk in adults with cardiovascular disease and obesity or overweight

23.34

★★★★★5.0 (157)

Heart disease: Semaglutide may reduce risk by up to 20% in 6 months

25.78

★★★★★4.7 (84)

International Clinical Trial Finds that Semaglutide Reduced Cardiovascular Events by 20% in Adults with Overweight or Obesity Who Don't Have Diabetes

25.43

★★★★★4.9 (203)

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

28.16

★★★★★5.0 (176)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

23.95

★★★★★4.8 (132)